Abbvie Inc
XBER:4AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Abbvie Inc
XBER:4AB
|
US |
|
Beiersdorf AG
OTC:BDRFF
|
DE |
|
S
|
Saipem SpA
OTC:SAPMY
|
IT |
|
Audax Renovables SA
F:54F
|
ES |
|
R
|
Ryanair Holdings PLC
XBER:RY4C
|
IE |
Wall St Price Targets
4AB Price Targets Summary
Abbvie Inc
According to Wall Street analysts, the average 1-year price target for 4AB is 219.66 EUR with a low forecast of 159.13 EUR and a high forecast of 275.76 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 4AB's stock price target?
Price Target
219.66
EUR
According to Wall Street analysts, the average 1-year price target for 4AB is 219.66 EUR with a low forecast of 159.13 EUR and a high forecast of 275.76 EUR.
What is the Revenue forecast for Abbvie Inc?
Projected CAGR
5%
Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 5%.
What is the Gross Profit forecast for Abbvie Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Abbvie Inc?
Projected CAGR
12%
Over the last 13 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 8 years is 12%.
What is the Pre-Tax Income forecast for Abbvie Inc?
Projected CAGR
82%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 1%. The projected CAGR for the next 3 years is 82%.
What is the Net Income forecast for Abbvie Inc?
Projected CAGR
31%
Over the last 13 years, the compound annual growth rate for Net Income has been -2%. The projected CAGR for the next 8 years is 31%.
